VeriSilicon's AI-ISP Custom Chip Solution Enables Mass Production of Customer's Smartphones
Article content
Providing architecture design, software-hardware co-development, and mass production support, and enhancing AI-powered imaging
Article content
Article content
SHANGHAI — VeriSilicon (688521.SH) recently announced that its AI-ISP custom chip solution has been successfully adopted in a customer's mass-produced smartphones, reaffirming the company's comprehensive one-stop custom silicon service capabilities in AI vision processing.
Article content
VeriSilicon's AI-ISP custom chip solution can integrate proprietary or third-party Neural Network Processing Unit (NPU) IP and Image Signal Processing (ISP) IP. By combining traditional image processing techniques with AI algorithms, it significantly enhances image and video clarity, dynamic range, and environmental adaptability. The chip solution offers flexible configurations with RISC-V or Arm-based processors, supports MIPI image input/output interfaces, provides LPDDR5/4X memory integration capability, and is compatible with common peripheral interfaces such as UART, I2C, and SDIO. This makes the solution highly adaptable for deployment across various applications including smartphones, surveillance systems, and automotive electronics.
Article content
For this collaboration, VeriSilicon designed a low-power AI-ISP system-on-chip (SoC) based on the RISC-V architecture, tailored to the customer's specific requirements. It also included a FreeRTOS real-time Software Development Kit (SDK). The customized SoC was fully optimized for seamless interoperability with the customer's main processor platform and has since been successfully deployed in multiple smart devices, achieving large-scale production. This success highlights VeriSilicon's robust capabilities in heterogeneous computing, software-hardware co-optimization, and system-level integration and verification.
Article content
'AI-powered imaging has become a key differentiator in the competitive smartphone market, driving increasing demand for high-performance and low-power image processing solutions,' said Wiseway Wang, Executive Vice President and General Manager of the Custom Silicon Platform Division at VeriSilicon. 'With full-spectrum capabilities ranging from IP licensing and chip architecture design to system-level software and hardware development, tape-out, packaging and testing, as well as mass production, VeriSilicon offers end-to-end custom silicon services leveraging its extensive design service experience and proven mass production capabilities. The successful mass production of this customer's chip further validates our strength in high-end silicon design services. Moving forward, we will continue to innovate and improve our offerings, empowering customers to accelerate the launch of differentiated products with efficient, high-quality custom chip solutions.'
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
35 minutes ago
- Winnipeg Free Press
Meta invests in AI firm Scale and recruits its CEO for ‘superintelligence' team
Meta said Thursday it is making a large investment in artificial intelligence company Scale and recruiting its CEO Alexandr Wang to join a team developing 'superintelligence' at the tech giant. The move reflects a push by Meta CEO Mark Zuckerberg to revive AI efforts at the parent company of Facebook and Instagram as it faces tough competition from competitors such as Google and OpenAI. Meta announced what it called a 'strategic partnership and investment' with Scale late Thursday but didn't disclose the financial terms of the deal. Scale said the added investment puts its market value at over $29 billion. It won't be the first time a big tech company has gobbled up talent and products at innovative AI startups without formally acquiring them. Microsoft hired key staff from startup Inflection AI, including co-founder and CEO Mustafa Suleyman, who now runs Microsoft's AI division. Google pulled in the leaders of AI chatbot company while Amazon made a deal with San Francisco-based Adept that sent its CEO and key employees to the e-commerce giant. Amazon also got a license to Adept's AI systems and datasets. Wang was a 19-year-old student at the Massachusetts Institute of Technology when he and co-founder Lucy Guo started Scale in 2016. They won influential backing that summer from the startup incubator Y Combinator, which was led at the time by Sam Altman, now the CEO of OpenAI. Wang dropped out of MIT, following a trajectory similar to that of Meta CEO Mark Zuckerberg, who quit Harvard University to start Facebook more than a decade earlier. Scale's pitch was to supply the human labor needed to improve AI systems, hiring workers to draw boxes around a pedestrian or a dog in a street photo so that self-driving cars could better predict what's in front of them. General Motors and Toyota have been among Scale's customers. What Scale offered to AI developers was a more tailored version of Amazon's Mechanical Turk, which had long been a go-to service for matching freelance workers with temporary online jobs. More recently, the growing commercialization of AI large language models — the technology behind OpenAI's ChatGPT, Google's Gemini and Meta's Llama — brought a new market for Scale's annotation teams. The company claims to service 'every leading large language model,' including from Anthropic, OpenAI, Meta and Microsoft, by helping to fine tune their training data and test their performance. It's not clear what the Meta deal will mean for Scale's other customers. Wang has also sought to build close relationships with the U.S. government, winning military contracts to supply AI tools to the Pentagon and attending President Donald Trump's inauguration. The head of Trump's science and technology office, Michael Kratsios, was an executive at Scale for the four years between Trump's first and second terms. Meta has also begun providing AI services to the federal government. Meta has taken a different approach to AI than many of its rivals, releasing its flagship Llama system for free as an open-source product that enables people to use and modify some of its key components. Meta says more than a billion people use its AI products each month, but it's also widely seen as lagging behind competitors such as OpenAI and Google in encouraging consumer use of large language models, also known as LLMs. It hasn't yet released its purportedly most advanced model, Llama 4 Behemoth, despite previewing it in April as 'one of the smartest LLMs in the world and our most powerful yet.' Meta's chief AI scientist Yann LeCun, who in 2019 was a winner of computer science's top prize for his pioneering AI work, has expressed skepticism about the tech industry's current focus on large language models. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. 'How do we build AI systems that understand the physical world, that have persistent memory, that can reason and can plan?' LeCun asked at a French tech conference last year. These are all characteristics of intelligent behavior that large language models 'basically cannot do, or they can only do them in a very superficial, approximate way,' LeCun said. Instead, he emphasized Meta's interest in 'tracing a path towards human-level AI systems, or perhaps even superhuman.' LeCun co-founded Meta's AI research division more than a decade ago with Rob Fergus, a fellow professor at New York University. Fergus later left for Google but returned to Meta last month after a 5-year absence to run the research lab, replacing longtime director Joelle Pineau. Fergus wrote on LinkedIn last month that Meta's commitment to long-term AI research 'remains unwavering' and described the work as 'building human-level experiences that transform the way we interact with technology.'
Globe and Mail
2 hours ago
- Globe and Mail
Why AI Stock AppLovin Slumped Today
Very frequently, when a company's stock is targeted by a vociferous short selle r, it can take a hit to its share price. That was the dynamic behind AppLovin 's (NASDAQ: APP) 0.7% dip on Thursday after a notable "shortie" published a report that was highly critical of the company. That decline was a bit steeper than the 0.4% slide of the S&P 500 index that day. Alleged Chinese connections The short seller is a firm called Culper Research, and Thursday morning it laid out in a 30-page document its reasons for shorting AppLovin. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » These center around AppLovin's stated aim of owning the non-China operations of that country's runaway social media success, TikTok. Culper finds that problematic, not least due to what it considers to be significant investment in AppLovin's equity by a Chinese national, Hao Tang. It also expressed dismay about what it considers to be the company's undisclosed partnerships with two companies in the Asian country. Ultimately, wrote Culper, "AppLovin's covert Chinese ownership and operations raise not only concerns for shareholders but for national security and data security -- the very concerns AppLovin purports to address by acquiring TikTok's ex-China operations." The short seller added that Hao "is a bad actor with extensive direct and indirect ties to Chinese espionage, [Chinese Communist Party] state-sponsored propaganda, human trafficking, and money laundering operations." Muted reaction from the market The mild investor sell-off in the wake of Culper's report indicates that more than a few AppLovin shareholders aren't fully buying the firm's arguments. That said, the short seller does raise what might be valid concerns; AppLovin hasn't yet officially responded to the allegations, and it'll be worth watching to see if and when those apparent China connections come to light. Should you invest $1,000 in AppLovin right now? Before you buy stock in AppLovin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AppLovin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
3 hours ago
- Globe and Mail
Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
DelveInsight's, ' Diffuse Large B-Cell Lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL. DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment. The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies Diffuse Large B-Cell Lymphoma Emerging Drugs Profile Brentuximab vedotin: Pfizer Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. THOR-707: Sanofi THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. Abexinostat: Xynomic Pharmaceuticals Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma. RNK05047: Ranok Therapeutics RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints. BMF-219: Biomea Fusion BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. ADI-001: Adicet Bio ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma. The Diffuse Large B-Cell Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment. Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market. Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs Diffuse Large B-Cell Lymphoma Companies Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report Coverage- Global Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others. Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others. Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Diffuse Large B-Cell Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Brentuximab vedotin: Pfizer Drug profiles in the detailed report….. Mid Stage Products (Phase II) THOR-707: Sanofi Drug profiles in the detailed report….. Early Stage Products (Phase I) ADI-001: Adicet Bio Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diffuse Large B-Cell Lymphoma Key Companies Diffuse Large B-Cell Lymphoma Key Products Diffuse Large B-Cell Lymphoma- Unmet Needs Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion Diffuse Large B-Cell Lymphoma Analyst Views Diffuse Large B-Cell Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
